Helmholtz Young Investigator Group"Innate Immunomodulation"



  • Modulation of allergic and non-allergic airway inflammation
  • Immune-regulation of lipid mediator pathways


Type 2 immune responses confer protection against worm parasites (helminths), but also drive inflammation and immunopathology in allergy, asthma and nasal polyposis. The mission of the group is to explore regulatory mechanisms of type 2 immune responses to support the prevention and therapy of chronic inflammatory diseases.

Metabolites of the polyunsaturated fatty acid (PUFA) arachidonic acid (“eicosanoids”) play central and versatile roles in type 2 immune responses (https://www.ncbi.nlm.nih.gov/pubmed/28622139). However, current therapies fail to sufficiently target these important mediators. Thus, a particular focus of our work is to identify immunomodulatory mechanisms and molecules, which regulate eicosanoid-driven airway inflammation.

Macrophages accumulate on the surface of helminth larvae and start to express the enzyme cyclooxygenase-2 (red) and its positive regulator HIF-1α (green), allowing them to produce high levels of immuneregulatory prostaglandins.


Julia Esser-von Bieren, PhD

Helmholtz Young Investigator Group leader

Zentrum Allergie und Umwelt (ZAUM)
Technische Universität und Helmholtz Zentrum München

Biedersteiner Str. 29
80802 München

Phone: +49 89 4140-3464

We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.